大博医疗(002901) - 2020 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2020 was ¥230,304,243.38, representing a 5.89% increase compared to ¥217,501,203.83 in the same period last year[8]. - The net profit attributable to shareholders was ¥89,190,527.51, up 7.85% from ¥82,700,447.72 year-on-year[8]. - The net profit after deducting non-recurring gains and losses decreased by 6.62% to ¥68,943,151.81 from ¥73,832,663.91 in the previous year[8]. - The basic earnings per share for the period was ¥0.22, a 4.76% increase from ¥0.21 in the same period last year[8]. - The weighted average return on net assets was 5.05%, down from 5.58% in the previous year[8]. - Total operating revenue for the current period reached ¥230,304,243.38, an increase from ¥217,501,203.83 in the previous period, representing a growth of approximately 5.8%[38]. - Net profit for the current period was ¥89,492,535.97, compared to ¥85,915,896.51 in the previous period, reflecting an increase of approximately 3.0%[40]. - The total profit for the current period was ¥106,055,139.17, compared to ¥104,193,814.96 in the previous period, indicating a growth of about 1.8%[40]. - Comprehensive income for the current period totaled ¥86,697,207.88, slightly up from ¥85,954,070.48 in the previous period[41]. Cash Flow - The net cash flow from operating activities was negative at -¥8,235,865.28, a decline of 125.16% compared to ¥32,733,896.57 in the same period last year[8]. - Cash received from other operating activities increased by 168.27% to ¥25,209,568.12 from ¥9,397,078.38, primarily due to higher government subsidies[19]. - Cash paid for operating activities increased by 206.11% to ¥82,127,296.13 from ¥26,829,182.48, largely due to increased market promotion expenses[19]. - Operating cash inflow totaled CNY 266,198,063.15, an increase of 24.4% from CNY 213,900,427.60 in the previous period[48]. - The company reported a net increase in cash and cash equivalents of CNY 16,716,522.10, compared to a decrease of CNY -33,583,085.67 in the previous period[49]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,266,235,337.12, an increase of 1.23% from ¥2,238,773,031.97 at the end of the previous year[8]. - The total liabilities decreased to CNY 421,013,802.70 from CNY 485,310,074.39, a reduction of about 13.2%[32]. - The company's equity attributable to shareholders increased to CNY 1,812,928,947.69 from CNY 1,721,832,928.59, showing a growth of approximately 5.3%[33]. - The company reported a decrease in current liabilities to CNY 363,684,950.82 from CNY 425,753,582.13, a decline of approximately 14.6%[32]. - Total assets amounted to CNY 2,238,773,031.97, with non-current assets totaling CNY 591,066,638.88[55]. Expenses - Total operating costs amounted to ¥146,747,056.04, up from ¥114,607,844.51, indicating a rise of about 28.0%[39]. - Research and development expenses increased by 35.20% to ¥24,639,137.42 from ¥18,223,591.57, reflecting higher personnel costs and increased investment in new product development[18]. - Sales expenses rose by 57.84% to ¥86,875,731.80 from ¥55,039,458.93, driven by increased market development and technical service costs[18]. - The company reported a decrease in tax expenses to ¥16,562,603.20 from ¥18,277,918.45, a reduction of approximately 9.4%[40]. Government Subsidies - The company received government subsidies amounting to ¥23,806,269.18 during the reporting period[9]. - Other income surged by 652.16% to ¥23,806,269.18 from ¥3,165,074.42, mainly due to increased government subsidies received during the period[18].